Focused On-demand Library for Eyes absent homolog 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O95677

UPID:

EYA4_HUMAN

Alternative names:

Alternative UPACC:

O95677; B7Z7F7; O95464; O95679; Q8IW39; Q9NTR7

Background:

Eyes absent homolog 4 (EYA4) plays a pivotal role in DNA repair and organogenesis, specifically through its function as a tyrosine phosphatase. It dephosphorylates 'Tyr-142' of histone H2AX, facilitating the recruitment of DNA repair complexes and distinguishing between apoptotic and repair responses to genotoxic stress. Its involvement in the development of the eye highlights its significance in biological systems.

Therapeutic significance:

EYA4's association with autosomal dominant deafness and dilated cardiomyopathy underscores its therapeutic potential. Understanding the role of Eyes absent homolog 4 could open doors to potential therapeutic strategies for treating sensorineural hearing loss and heart failure, offering hope for patients suffering from these conditions.